Skip to main content

Advertisement

Table 1 Patient characteristics and treatment outcomes

From: Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

Responders
Patient ID RECIST at Week 12 Baseline LDH (U/L) PFS (months)a OS (months)a
G1 PR 167 Response ongoing Alive
G2 PR 215 Response ongoing Alive
G3 PR 159 Response ongoing Alive
G4 PR 217 Response ongoing Alive
G5 PR 185 Response ongoing Alive
G6 PR 206 Response ongoing Alive
G7 PR 268 Response ongoing Alive
G8 PR 167 Response ongoing Alive
G9 PR 227 Response ongoing Alive
G10 PR 187 Response ongoing Alive
G11 PR 140 Response ongoing Alive
G12 CR 150 Response ongoing Alive
Non-responders
Patient ID RECIST at Week 12 Baseline LDH (U/L) PFS (months)a OS (months)a
P1 PD 303 2.7 5.8
P2 PD 568 2.7 5.1
P3 PD 329 2.7 3.1
P4 PD 300 1.1 Alive
P5 PD 271 0.5 Alive
P6 PD 267 2.7 Alive
P7 PD 169 2.8 Alive
P8 SD 226 4 Alive
P9 SD 269 4.1 Alive
P10 SD 176 2.7 21.7
P11 SD 195 Response ongoing Alive
P12 SD 402 5.5 8.3
  1. Abbreviations: PR partial response, SD stable disease, PD progressive disease, CR complete response, LDH lactate dehydrogenase, PFS progression free survival, OS overall survival, U/L units per liter
  2. aData cut off on 30th April, 2017. 11 out of 24 patients had progressed at time of analysis, all of whom were in the non-responders group. Median follow-up for these patients is 24.3 months. Normal range of LDH is 120–250 U/L